SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 373,446.63 |
| Enterprise Value ($M) | 387,224.63 |
| Book Value ($M) | 71,490.00 |
| Book Value / Share | 29.71 |
| Price / Book | 5.17 |
| NCAV ($M) | -44,011.00 |
| NCAV / Share | -18.29 |
| Price / NCAV | -8.49 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.17 |
| Return on Assets (ROA) | 0.13 |
| Return on Equity (ROE) | 0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.03 |
| Current Ratio | 1.26 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 71,551.00 |
| Assets | 193,671.00 |
| Liabilities | 115,562.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 88,821.00 |
| Operating Income | 21,249.00 |
| Net Income | 14,066.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 24,266.00 |
| Cash from Investing | -18,599.00 |
| Cash from Financing | -3,132.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,403,189 | 6,751,548 | 20.78 | |
| 997,183 | 4,461,051 | 22.35 | |
| 1,292,704 | 4,791,512 | 26.98 | |
| 880,928 | 4,803,091 | 18.34 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EBS – Emergent BioSolutions Inc. | ELAN – Elanco Animal Health Incorporated |
| HYAC – Haymaker Acquisition Corp. 4 | LLY – Eli Lilly and Company |
| MRK – Merck & Co., Inc. |